ABVD versus BEACOPP for Hodgkin's lymphoma [2]

New England Journal of Medicine

Volumn 365, Issue 16, 2011, Pages 1545-1546

  Borchmann, Peter ^a   Diehl, Volker ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HODGKIN DISEASE; HUMAN; LETTER; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; UNITED STATES; FEMALE; MALE; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; MALE;

EID: 80054728759     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (1)

1. Surveillance, Epidemiology, and End Results Cancer Statistics Review 1975-2008. Bethesda, MD: National Cancer Institute, 2011. (http://seer.cancer. gov/csr/1975-2008.)